- Home >
- Clinicals Trials >
- MK-2870-004
Retour à la liste des essais cliniquesLung cancer
MK-2870-004
A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy;(Docetaxel or Pemetrexed) in Previously Treated Advanced or Metastatic Nonsquamous;Non-small Cell Lung Cancer (NSCLC) with EGFR Mutations or Other Genomic Alterations.
- Ouvert à Paris depuis le : 08/11/2024
- Public cible : Adult
- Phase : Phase III
Description de l'essai
To compare MK-2870 to chemotherapy;with respect to PFS per RECIST 1.1 as;assessed by BICR in NSCLC with EGFR;mutations.;Hypothesis (H1): MK-2870 is superior to;chemotherapy with respect to PFS per;RECIST 1.1 as assessed by BICR in;NSCLC with EGFR mutations.To compare MK-2870 to chemotherapy;with respect to OS in NSCLC with EGFR;mutations.;Hypothesis (H2): MK-2870 is superior to;chemotherapy with respect to OS in;NSCLC with EGFR mutations.
Url of the trialInvestigateur principal
